Chidamide plus R-GDP for relapsed/refractory diffuse large B-cell lymphoma in patients ineligible for autologous transplantation: A prospective, single-arm, phase II study.
Guang-Liang ChenKai XueQunling ZhangZu-Guang XiaJia JinRan LiYi-Zhen LiuFangfang LvXiaonan HongXiaoqiu LiJunning CaoPublished in: Cancer medicine (2024)
Chidamide combined with R-GDP is a safe and effective treatment option for patients with R/R DLBCL who are not eligible for autologous stem cell transplantation.
Keyphrases
- diffuse large b cell lymphoma
- stem cell transplantation
- phase ii study
- epstein barr virus
- end stage renal disease
- high dose
- cell therapy
- bone marrow
- newly diagnosed
- ejection fraction
- chronic kidney disease
- acute lymphoblastic leukemia
- open label
- prognostic factors
- clinical trial
- randomized controlled trial
- radiation therapy
- platelet rich plasma
- mesenchymal stem cells
- hodgkin lymphoma
- combination therapy
- multiple myeloma
- placebo controlled